This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple
negative breast cancer.
Seventy to eighty percent of breast cancers have a gene expression profile which is
characterized by homologous recombination deficiency (HRD) and high proliferation. HRD leads
to errors in DNA pathway [non -homologous end joining (NHEJ)] that repair DNA-breaks, a
process required for metastatic triple negative breast cancer (TNBC) survival. The hypothesis
of this pilot trial is that administration of LY3023414 and prexasertib will inhibit NHEJ in
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.